Market Currents
Salix Pharmaceuticals (SLXP +7.1%) spikes higher on volume 3X normal trading activity after...
-
Tuesday, February 28, 2012, 12:24 PM ETSalix Pharmaceuticals (SLXP +7.1%) spikes higher on volume 3X normal trading activity after Auriga upgrades it to a Buy rating with a $54 price target. Analysts call the firm's 2012 guidance conservative and indicate that they see a high likelihood that Salix will outperform.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
